Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients

Wang, Jinhao; Liu, Yaxin; Liang, Yeru; Zhang, Yue; Hua, Dong; Zheng, Tiantian; Yu, Jianjun; Du, Pan; Jia, Shidong; King, Bonnie L.; Wang, Jing; Liu, Xiaoran; Li, Huiping

doi:10.3389/fonc.2023.1152575

Cited by 2 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Briefly, cell-free DNA (cfDNA) were subjected to library construction. PredicineCARE targeted hybridization enrichment assay was used to generate the landscape of genomic alterations including singlenucleotide variants (SNV), insertions and deletions (indels), CNVs, and gene fusions [34][35][36][37] . PredicineSCORE low pass whole genome sequencing assay was used to generate 9 copy number profiles and genome-wide copy number burden (CNB) score, which represents a comprehensive genome-wide measure of copy number status, including amplifications and deletions if any, across the entire chromosome arms.…”

Section: Cell-free Dna Extraction and Sequencingmentioning

confidence: 99%

Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA: one patient at a time

Riviere-Cazaux,

Dong,

et al. 2024

Preprint

View full text Add to dashboard Cite

IMPORTANCECurrent methods for glioma treatment response assessment are limited. Intracranial cerebrospinal fluid (CSF) may provide a previously untapped source of longitudinal biomarkers, such as cell-free DNA (cfDNA), for disease monitoring.OBJECTIVETo assess the feasibility of obtaining longitudinal intracranial CSF cfDNA from patients with gliomas during their disease course.DESIGNThis case series was initiated in 2021, with patients followed until last clinical follow-up (death or present time).SETTINGThis single-center study was conducted at a large academic medical center.PARTICIPANTSAdults with gliomas were recruited for longitudinal intracranial CSF collection using 1) Ommaya reservoirs, from which CSF would be sampled on at least two separate occasions, or 2) CSF collection from other clinically indicated CSF access devices, such as ventriculoperitoneal (VP) shunts.INTERVENTIONSCSF was collected from Ommaya reservoirs in four patients and from an existing VP shunt in one patient.MAIN OUTCOMES AND MEASURESThe study aimed to collect CSF for biobanking and biomarker discovery, with the hypothesis that CSF could serve as a source of longitudinally acquirable biomarkers.RESULTSFive patients (2 females, 3 males; median: 40 years, range 32-64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n=4/5 patients) or VP shunt (n=1/5). Three patients had glioblastoma and two had astrocytoma, IDH-mutant, grade 4. In total, thirty-five CSF samples were obtained (median: 3.80 mL; 0.5-5 mL), with 30 (85.7%) yielding sufficient cfDNA for Next-Generation Sequencing (n=28) or Low-Pass Whole Genome sequencing (all samples). Tumor fraction was found to increase with radiographic progression. Changes in variant allelic frequencies (VAFs) may be seen within individual patients after resection and chemoradiation. In two patients, changes in tumor-specific IDH1 VAF correlated with CSF D-2-hydroxyglutarate levels, the oncometabolite of IDH mutant tumors. Copy number burden (CNB) decreased below the limit of quantification during treatment.CONCLUSIONS AND RELEVANCELongitudinal CSF cfDNA can feasibly be obtained via CSF access devices in patients with gliomas during their disease course. Ongoing studies will evaluate hypotheses generated in this case series regarding how longitudinal CSF cfDNA could be utilized to sensitively detect changes in disease burden.Trial RegistrationNCT04692324https://clinicaltrials.gov/study/NCT04692324;NCT04692337https://clinicaltrials.gov/study/NCT04692337QUESTIONWhat is the feasibility of obtaining longitudinal intracranial cerebrospinal fluid cell-free DNA from patients with high-grade gliomas to evaluate changes during treatment?FINDINGIn this case series, we find that CSF cfDNA can feasibly be obtained throughout treatment via CSF access devices. We find that changes in tumor fraction or tumor-associated variant allele frequencies (VAFs) may correlate with disease trajectory, with VAFs positively correlating to other tumor-associated candidate biomarkers.MEANINGLongitudinal cerebrospinal cell-free DNA may inform the impact of treatment throughout a specific patient’s disease course, from the time of resection through radiographic progression.

show abstract

Section: Cell-free Dna Extraction and Sequencingmentioning

confidence: 99%

Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA: one patient at a time

Riviere-Cazaux,

Dong,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Overall survival and disease‐free survival prediction in Chinese women with breast cancer aged 70 years or older by using nomograms

Feng,

Huang,

Min

et al. 2024

Evaluation Clinical Practice

View full text Add to dashboard Cite

PurposeBy analyzing the existing data of this study, a prediction tool for the overall breast cancer survival and disease‐free survival (DFS) of elderly women was established.Patients and MethodsClinicopathologic data were collected from elderly women with BC who were admitted to the Tianjin Medical University Cancer Institute and Hospital from August 2014 to December 2017. Independent prognostic factors for BC in elderly patients were confirmed using the Cox proportional hazards model. Nomograms were developed with these factors for predicting the 3‐ and 5‐year overall survival (OS) as well as DFS. The nomograms' discrimination ability and calibration were assessed through the area under the curve (AUC), concordance index (C‐index), decision curve analysis (DCA), and calibration plots.ResultsWe enroled 889 elderly patients with BC, and the results showed that the 3‐year OS rate was 93.4% (95%CI = 91.8%–95.1%), the 3‐year DFS rate was 87.8% (95%CI = 85.7%–90.0%), the 5‐year OS rate was 85.6% (95%CI = 83.3%–87.9%), and the 5‐year DFS rate was 80.1%(95%CI = 77.5%–82.8%). The corrected C‐indices of the OS and DFS nomograms were 0.799 and 0.667, respectively (95%CI = 0.767–0.830 and 0.632–0.702, respectively). Relatively high AUC values were shown by the nomograms for estimating OS and DFS. The DCA revealed that the constructed nomograms had net benefits for clinical application. The calibration curves demonstrated an excellent correspondence between the data predicted by the nomograms and the actual survival data. Survival curves indicated that risk stratification could differentiate OS and DFS.ConclusionsThis study developed novel and practical nomograms for individual prediction of DFS and OS in elderly BC patients. These nomograms can predict 3‐ and 5‐year OS as well as DFS in the elderly BC patient population, thereby enabling personalized risk assessment and risk‐based therapy.

show abstract

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients

Cited by 2 publications

References 58 publications

Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA: one patient at a time

Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA: one patient at a time

Overall survival and disease‐free survival prediction in Chinese women with breast cancer aged 70 years or older by using nomograms

Contact Info

Product

Resources

About